Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
Date:2/4/2008

enges and opportunities of 2008 and beyond. In 2008, those opportunities are expected to include the introduction of a number of important new CRM products, the lifting of the Corporate Warning Letter, the approval of the TAXUS Liberte and PROMUS(TM) stent systems by the FDA, and the launch of profitable new products across our businesses."

Fourth Quarter 2007

Net sales for the fourth quarter of 2007 were $2.152 billion, as compared to $2.065 billion for the fourth quarter of 2006. Worldwide sales of the Company's drug-eluting coronary stent systems were $435 million, as compared to $506 million. U.S. sales of drug-eluting coronary stent systems were $224 million, as compared to $329 million. International sales of drug-eluting coronary stent systems were $211 million, as compared to $177 million. Worldwide sales of coronary stent systems were $496 million, as compared to $550 million. U.S. sales of coronary stent systems were $250 million, as compared to $347 million. International sales of coronary stent systems were $246 million, as compared to $203 million.

Worldwide sales of the Company's CRM business for the fourth quarter of 2007 were $544 million, which included $396 million of implantable cardioverter defibrillator (ICD) sales, as compared to worldwide CRM sales of $489 million for the fourth quarter of 2006, which included $356 million of ICD sales. U.S. CRM sales were $347 million, which included $266 million of ICD sales, as compared to $320 million, which included $250 million of ICD sales. International CRM sales were $197 million, which included $130 million of ICD sales, as compared to $169 million, which included $106 million of ICD sales.

Reported net loss for the fourth quarter of 2007 was $458 million, or $0.31 per share. Reported results included acquisition, divestiture, litigation and restructuring-related charges and amortization expense (pre-tax) of $939 million, or $0.55 per share, which consisted of:


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Boston Scientific to Participate in Merrill Lynch Conference
2. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
5. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
6. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
7. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
8. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
9. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
10. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
11. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... the promotions of Linda Arterburn, PhD, Francisco Leon, MD, ... "We are pleased,to announce the promotions of several of ... a fine group of talented people working here to ... with celiac,disease, asthma, eye disorders, and other areas to ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
... OF PHASE II DATA FOR LEAD DRUG CANDIDATE ... Oct. 2 Transave, Inc., a,biopharmaceutical company focused ... of serious lung diseases,today announced that it has ... and Compass Horizon Funding Company LLC, an affiliate ...
Cached Biology Technology:Alba Therapeutics Corporation Announces Promotions 2Alba Therapeutics Corporation Announces Promotions 3Alba Therapeutics Corporation Announces Promotions 4DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5
(Date:4/24/2014)... and the University of North Carolina at Chapel Hill ... identify arterial plaque that is at high risk of ... At issue is the plaque that builds up in ... deemed "vulnerable," meaning that they are more likely to ... or stroke. , "Existing state-of-the-art technologies are capable of ...
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... data shows Africa,s Congo rainforest, the second-largest tropical rainforest ... greenness over the past decade. , The study, led ... of New York, shows between 2000 and 2012 the ... intensified. The research, published Wednesday in Nature , ... explore the effects of long-term drought on the Congo ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2Two new US turtle species described 2Two new US turtle species described 3NASA satellites show drought may take toll on Congo rainforest 2NASA satellites show drought may take toll on Congo rainforest 3
... The age at which a person takes a first ... drinkers the most susceptible to severe problems. A team ... Medicine in St. Louis, studied 6,257 adult twins from Australia. ... an early age are more likely to develop a more ...
... subsidies to fossil fuels are attributed to tax breaks ... be released on Friday by the Environmental Law Institute ... for Scholars. The study, which reviewed fossil fuel ... the lion,s share of energy subsidies supported energy sources ...
... Hopkins School of Medicine have discovered how one antioxidant ... the development of spinal cord neurons. The research, publishing ... known mechanism of protein control. "This is the ... control neuronal differentiation," says Shanthini Sockanathan, Ph.D., an associate ...
Cached Biology News:Young age at first drink may affect genes and risk for alcoholism 2Young age at first drink may affect genes and risk for alcoholism 3US tax breaks subsidize foreign oil production 2Antioxidant controls spinal cord development 2
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
Biology Products: